Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines

Vaccine

Volumn 29, Issue 34, 2011, Pages 5657-5665

  Khurana, Surender ^a   Larkin, Christopher ^a   Verma, Swati ^a   Joshi, Manju B ^a   Fontana, Juan ^b   Steven, Alasdair C ^b   King, Lisa R ^a   Manischewitz, Jody ^a   McCormick, William ^a   Gupta, Rajesh K ^a   Golding, Hana ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

H1N1; H5N1; Pandemic influenza; Single radial immunodiffusion assay; Vaccine; Vaccine potency

Indexed keywords

BACTERIUM ANTIBODY; INFLUENZA VACCINE; OLIGOMER; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN HA1; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; ESCHERICHIA COLI; GENE EXPRESSION SYSTEM; IMMUNODIFFUSION; INFLUENZA A (H1N1); INFLUENZA A (H5N1); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MASS IMMUNIZATION; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINE PRODUCTION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ESCHERICHIA COLI; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; RABBITS; RECOMBINANT PROTEINS; VACCINATION;

EID: 79960563634     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.06.014     Document Type: Article

References (30)

1. Wood J.M., Schild G.C., Newman R.W., Seagroatt V. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand 1977, 5(3):237-247.
2. Wood J.M., Dunleavy U., Newman R.W., Riley A.M., Robertson J.S., Minor P.D. The influence of the host cell on standardisation of influenza vaccine potency. Dev Biol Stand 1999, 98:183-188.
3. Williams M.S., Mayner R.E., Daniel N.J., Phelan M.A., Rastogi S.C., Bozeman F.M., et al. New developments in the measurement of the hemagglutinin content of influenza virus vaccines by single-radial-immunodiffusion. J Biol Stand 1980, 8(4):289-296.
4. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 2003, 21(16):1776-1779.
5. Compans R.W., Klenk H.D., Caliguiri L.A., Choppin P.W. Influenza virus proteins. I. Analysis of polypeptides of the virion and identification of spike glycoproteins. Virology 1970, 42(4):880-889.
6. Brand C.M., Skehel J.J. Crystalline antigen from the influenza virus envelope. Nat New Biol 1972, 238(83):145-147.
7. Schmeisser F., Vodeiko G.M., Lugovtsev V.Y., Stout R.R., Weir J.P. An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination. Vaccine 2010, 28(12):2442-2449.
8. Chun S., Li C., Van Domselaar G., Wang J., Farnsworth A., Cui X., et al. Universal antibodies and their applications to the quantitative determination of virtually all subtypes of the influenza A viral hemagglutinins. Vaccine 2008, 26(48):6068-6076.
9. Khurana S., Verma S., Verma N., Crevar C.J., Carter D.M., Manischewitz J., et al. Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus. PLoS One 2010, 5(7):e11548.
10. Khurana S., Verma S., Verma N., Crevar C.J., Carter D.M., Manischewitz J., et al. Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets. J Virol 2011, 85(3):1246-1256.
11. Khurana S., Suguitan A.L., Rivera Y., Simmons C.P., Lanzavecchia A., Sallusto F., et al. Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med 2009, 6(4):e1000049.
12. Heymann J.B., Belnap D.M. Bsoft: image processing and molecular modeling for electron microscopy. J Struct Biol 2007, 157(1):3-18.
13. Ludtke S.J., Baldwin P.R., Chiu W. EMAN: semiautomated software for high-resolution single-particle reconstructions. J Struct Biol 1999, 128(1):82-97.
14. Shaikh T.R., Gao H., Baxter W.T., Asturias F.J., Boisset N., Leith A., et al. SPIDER image processing for single-particle reconstruction of biological macromolecules from electron micrographs. Nat Protoc 2008, 3(12):1941-1974.
15. Wilson I.A., Skehel J.J., Wiley D.C. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3A resolution. Nature 1981, 289(5796):366-373.
16. Ruigrok R.W., Wrigley N.G., Calder L.J., Cusack S., Wharton S.A., Brown E.B., et al. Electron microscopy of the low pH structure of influenza virus haemagglutinin. EMBO J 1986, 5(1):41-49.
17. Shinde V., Bridges C.B., Uyeki T.M., Shu B., Balish A., Xu X., et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N Engl J Med 2009, 360(25):2616-2625.
18. Smith G.J., Vijaykrishna D., Bahl J., Lycett S.J., Worobey M., Pybus O.G., et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 2009, 459(7250):1122-1125.
19. Gatherer D. The 2009 H1N1 influenza outbreak in its historical context. J Clin Virol 2009, 45(3):174-178.
20. Peiris J.S., Poon L.L., Guan Y. Emergence of a novel swine-origin influenza A virus (S-OIV) H1N1 virus in humans. J Clin Virol 2009, 45(3):169-173.
21. Update: influenza activity-United States, 2009-10 season. MMWR Morb Mortal Wkly Rep 2010, 59(29):901-908.
22. Abelin A., Colegate T., Gardner S., Hehme N., Palache A. Lessons from pandemic influenza A(H1N1): the research-based vaccine industry's perspective. Vaccine 2010, 29(6):1135-1138.
23. Kapteyn J.C., Porre A.M., de Rond E.J., Hessels W.B., Tijms M.A., Kessen H., et al. HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines. Vaccine 2009, 27(9):1468-1477.
24. Garcia-Canas V., Lorbetskie B., Bertrand D., Cyr T.D., Girard M. Selective and quantitative detection of influenza virus proteins in commercial vaccines using two-dimensional high-performance liquid chromatography and fluorescence detection. Anal Chem 2007, 79(8):3164-3172.
25. Williams T.L., Luna L., Guo Z., Cox N.J., Pirkle J.L., Donis R.O., et al. Quantification of influenza virus hemagglutinins in complex mixtures using isotope dilution tandem mass spectrometry. Vaccine 2008, 26(20):2510-2520.
26. Hashem A.M., Van Domselaar G., Li C., Wang J., She Y.M., Cyr T.D., et al. Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus. Biochem Biophys Res Commun 2010, 403(2):247-251.
27. Li C., Shao M., Cui X., Song Y., Li J., Yuan L., et al. Application of deglycosylation and electrophoresis to the quantification of influenza viral hemagglutinins facilitating the production of 2009 pandemic influenza (H1N1) vaccines at multiple manufacturing sites in China. Biologicals 2010, 38(2):284-289.
28. Treanor J.J., Wilkinson B.E., Masseoud F., Hu-Primmer J., Battaglia R., O'Brien D., et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001, 19(13-14):1732-1737.
29. Lakey D.L., Treanor J.J., Betts R.F., Smith G.E., Thompson J., Sannella E., et al. Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J Infect Dis 1996, 174(4):838-841.
30. Wei C.J., Xu L., Kong W.P., Shi W., Canis K., Stevens J., et al. Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J Virol 2008, 82(13):6200-6208.